PURPOSE: Androgen receptor (AR) is expressed in the majority of human prostate cancers. For a better understanding of prostate carcinoma events it is necessary to present findings on the regulation of AR target genes, AR interaction with associated proteins, ligand independent activation and point mutations. MATERIALS AND METHODS: A comprehensive literature review of manuscripts published on AR in prostate cancer was performed using PubMed. RESULTS: AR regulates the expression of genes involved in the proliferation and differentiation of prostate cancer cells. Due to differential interactions with coactivators and corepressors AR activation results in the stimulation of a mitogenic response or in the expression of secretory proteins. AR is functional in advanced carcinoma of the prostate, as evidenced in studies of mutant receptors and ligand independent activation. AR point mutations appear in advanced prostate cancer more frequently than in organ confined disease. CONCLUSIONS: Current therapy options aimed to inhibit AR function in prostate cancer are limited. Antiandrogenic drugs frequently acquire agonistic properties in the presence of mutated ARs. In addition, androgen signaling pathway activity increases during long-term androgen ablation. AR coactivator complexes might be a target for novel therapies for prostate cancer.
PURPOSE:Androgen receptor (AR) is expressed in the majority of humanprostate cancers. For a better understanding of prostate carcinoma events it is necessary to present findings on the regulation of AR target genes, AR interaction with associated proteins, ligand independent activation and point mutations. MATERIALS AND METHODS: A comprehensive literature review of manuscripts published on AR in prostate cancer was performed using PubMed. RESULTS:AR regulates the expression of genes involved in the proliferation and differentiation of prostate cancer cells. Due to differential interactions with coactivators and corepressors AR activation results in the stimulation of a mitogenic response or in the expression of secretory proteins. AR is functional in advanced carcinoma of the prostate, as evidenced in studies of mutant receptors and ligand independent activation. AR point mutations appear in advanced prostate cancer more frequently than in organ confined disease. CONCLUSIONS: Current therapy options aimed to inhibit AR function in prostate cancer are limited. Antiandrogenic drugs frequently acquire agonistic properties in the presence of mutated ARs. In addition, androgen signaling pathway activity increases during long-term androgen ablation. AR coactivator complexes might be a target for novel therapies for prostate cancer.
Authors: Ferenc G Rick; Andrew V Schally; Luca Szalontay; Norman L Block; Karoly Szepeshazi; Mehrdad Nadji; Marta Zarandi; Florian Hohla; Stefan Buchholz; Stephan Seitz Journal: Proc Natl Acad Sci U S A Date: 2012-01-18 Impact factor: 11.205
Authors: A Rodriguez-Gonzalez; K Cyrus; M Salcius; K Kim; C M Crews; R J Deshaies; K M Sakamoto Journal: Oncogene Date: 2008-09-15 Impact factor: 9.867
Authors: Jan-Hendrik Bebermeier; James D Brooks; Samuel E DePrimo; Ralf Werner; Uta Deppe; Janos Demeter; Olaf Hiort; Paul-Martin Holterhus Journal: J Mol Med (Berl) Date: 2006-08-24 Impact factor: 4.599
Authors: Katayoon H Emami; Lisha G Brown; Tiffany E M Pitts; Xizhang Sun; Robert L Vessella; Eva Corey Journal: Prostate Date: 2009-10-01 Impact factor: 4.104
Authors: Thomas Nelius; Stephanie Filleur; Alexander Yemelyanov; Irina Budunova; E Shroff; Yelena Mirochnik; Arin Aurora; Dorina Veliceasa; Wuhan Xiao; Zhou Wang; Olga V Volpert Journal: Int J Cancer Date: 2007-09-01 Impact factor: 7.396